Ovid Therapeutics (OVID) Total Non-Current Liabilities (2018 - 2022)

Ovid Therapeutics (OVID) has reported Total Non-Current Liabilities for 5 consecutive years, with $26.1 million the latest figure, recorded in Q1 2022.

• For the quarter ending Q1 2022, Total Non-Current Liabilities rose 59.67% year-over-year to $26.1 million; the trailing twelve-month figure through Mar 2022 stood at $26.1 million (up 59.67% YoY), and the FY2021 full-year result was $14.8 million, down 54.18% from the prior year.
• Total Non-Current Liabilities rose to $26.1 million in Q1 2022 per OVID's latest filing, from $14.8 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $32.3 million in Q4 2020 and bottomed at $8.8 million in Q4 2018.
• Historically, Total Non-Current Liabilities has averaged $15.2 million across 5 years, with a median of $11.1 million in 2019.
• The sharpest annual moves came in 2020 and 2021: Total Non-Current Liabilities soared 198.46% in 2020, then tumbled 64.0% in 2021.
• Over 5 years, Total Non-Current Liabilities stood at $8.8 million in 2018, then increased by 22.34% to $10.8 million in 2019, then surged by 198.46% to $32.3 million in 2020, then tumbled by 54.18% to $14.8 million in 2021, then soared by 76.37% to $26.1 million in 2022.
• According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $26.1 million, $14.8 million, and $10.1 million for Q1 2022, Q4 2021, and Q3 2021 respectively.